

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/544,239
Filing Date	August 2, 2005
First Named Inventor	Lutz HILBRICH
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	1/1461 PCT

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code* ² Number* ³ Kind Code* ⁴ (If known)	MM-DD-YYYY			
/GP/		WO 01/72309 A2	10-04-2001	MEDICURE INTERNATIONAL INC.		
/GP/		WO 03/020243 A1	03-13-2003	LONGWOOD PHARMACEUTICAL RESEARCH, INC.		

Examiner Signature	/Gregg Polansky/	Date Considered	06/21/2007
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

100-8-12 PCT/PTC 02 AUG 2005
PTC/SA/08a (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number	Not Yet Assigned
--------------------	------------------

Filing Date	Not Yet Assigned
-------------	------------------

First Named Inventor	Lutz HILBRICH
----------------------	---------------

Art Unit	Not Yet Assigned
----------	------------------

Examiner Name	Not Yet Assigned
---------------	------------------

Attorney Docket Number	1/1461 PCT
------------------------	------------

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ³ (if known)				
/GP/		WO 01/30353	05-03-2001	Boehringer Ingelheim Pharma KG		
/GP/		WO 01/15673	03-08-2001	Aventis Pharma Deutschland GmbH		

06/21/2007

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				<i>Application Number</i>	Not Yet Assigned
				<i>Filing Date</i>	Not Yet Assigned
				<i>First Named Inventor</i>	Lutz HILBRICH
				<i>Art Unit</i>	Not Yet Assigned
				<i>Examiner Name</i>	Not Yet Assigned
<i>Sheet</i>	2	of	2	<i>Attorney Docket Number</i>	1/1461 PCT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/GP/		"Aggrenox: A Combination of Antiplatelet Drugs for Stroke Prevention", The Medical Letter on Drugs and Therapeutics, Vol. 42, Issue 1071, 2000, pp 11-12	
/GP/		A.J. SCHEEN "La combinaison fixe dipyridamole - acide acetylsalicylique (Aggrenox) Extended-Release Dipyridamole/Aspirin (Aggrenoxarhou)", Revue Medicale De Liege, Vol. 55, no. 10, 2000, pgs 957-959	
/GP/		A.I. MALININ, et al. "Aggrenox (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events", Heart Drug, Vol. 2, No. 2, 2002, pgs 93-104	
/GP/		Boehringer Ingelheim News, 'Online' "Largest-Ever Stroke Prevention Trial Launched" 2003	

Examiner Signature	/Gregg Polansky/	Date Considered	06/21/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.